Tatva Chintan Pharma Chem Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c8qrs6ieobexv90v68din1ev.pdf

Key Takeaways


The FY25 Miss: Price, Not Volume

Chintan Shah: "While I spoke to my customers, I understand that over the span of last 25 years, such incidences have happened three times. This is the third incident where suddenly the markets moved to gas when the gas products became cheap and again switch back to fuel when the gas prices started to rise."

PASC (Agro Intermediates): The New Growth Engine

Chintan Shah: "Tatva Chintan is the first company globally to produce it commercially by an alternative route of synthesis. So this is where we are bringing our catalytic technology in play on this product, which has helped us to achieve this milestone."

SDA: Betting on a Recovery


Electrolyte Salts & Newer Verticals

Chintan Shah: "Yes. So we are sending our samples. So basically, we have achieved the desired quality. Absolutely everything below 10 PPB levels has been achieved inside the reactor. Now we are waiting for the right packaging material."

New Customer Commercialization Pipeline

Chintan Shah: "Material is being delivered this Wednesday, the day after tomorrow to the customer. So after that, we will have maybe 4 to 6 weeks to know what is happening there."

Margins & Capex


Guidance & Commitments

CommitmentSpecificsTimeline
Topline growthOver 25% overall revenue growthFY26
EBITDA margin20-21% full-year, significant H1/H2 splitFY26
SDA segment growthAt least 40% growthFY26
PASC segment growthAt least 40% growthFY26
Electrolyte salts growthAt least 200% growth, from ~₹6 cr to ₹23-26 crFY26
Agro intermediate commercial supplyBulk order execution beginsQ3 FY26
New plant operational₹105-110 cr capex, agro intermediate facilityBefore January 2026
Operational efficiencyMost processes at optimum levelEnd of June 2025
Photo chlorination commercializationPost final validation by JuneWithin FY26
Pharma intermediates commercializationDepends on customer validation cyclesPossible by end FY26
SDA plant full-utilization revenue potential~₹450 cr topline at current pricesNo timeline (aspirational)

Key Metrics

MetricQ4 FY25
Revenue from operations₹107.9 cr, +10% YoY and +26% QoQ
EBITDA₹9 cr, -43% YoY and +27% QoQ
EBITDA margin8.3%, vs 15.9% in Q4 FY24
PAT₹1 cr, vs ₹9.6 cr in Q4 FY24; PAT margin 1.0% vs 9.8%
Exports₹66.2 cr, 61% of revenue
PTC segment revenue₹38.9 cr, +43% YoY and +32% QoQ
SDA segment revenue₹34.6 cr, -15% YoY and +51% QoQ
Pharma & Agro Intermediates and Specialty Chemicals revenue₹32.7 cr, +17% YoY and +10% QoQ
Electrolyte Salts segment revenue₹0.9 cr, -36% YoY and -65% QoQ
FY26 revenue growth guidanceOver 25% YoY, with strong recovery in H2
FY26 EBITDA margin guidanceAround 20%, full-year basis
SDA segment FY26 growth guidance40% to 70% in volume and value
PASC segment FY26 growth guidanceAt least 40%
Electrolyte Salts segment FY26 growth guidanceAt least 200%, from ~₹6 cr to ₹23-26 cr
SDA plant capacity utilization29% to 32%, improving since last one month
Non-SDA plant occupancy83% to 84%
New plant CAPEX₹105-110 cr, targeted operational before January 2026